Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (774)	2/12/2000 1:19:00 AM
From: John McCarthy	Read Replies (1) \| Respond to of 1494

Dr. John M. <<The neurotoxicity caused by Tat and gp120 applied in combination was blocked completely by memantine, partially by amiloride, and not at all by dipyridamole or vigabatrin>> In a word ......... WOW <vbg> My nutty time ............... John, don't know why I'm saying this - nonetheless ...... NTII has the feel of those types of companies that ELAN likes to get involved in ........... I do not own ELAN ......... but follow them they (NTII) has the look (downstream on clinicals) and feel (needs cash) that ELAN (into brain stuff) likes to screw around with ........ regards, John McCarthy